Procyon Advisors, LLC Halozyme Therapeutics, Inc. Transaction History
Procyon Advisors, LLC
- $1.61 Billion
- Q1 2025
A detailed history of Procyon Advisors, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Procyon Advisors, LLC holds 4,625 shares of HALO stock, worth $259,323. This represents 0.02% of its overall portfolio holdings.
Number of Shares
4,625
Previous 4,471
3.44%
Holding current value
$259,323
Previous $213,000
38.5%
% of portfolio
0.02%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding HALO
# of Institutions
595Shares Held
124MCall Options Held
320KPut Options Held
113K-
Black Rock Inc. New York, NY17.6MShares$988 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$719 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$339 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$218 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$206 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.81B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...